CS
GLMD icon

Credit Suisse’s Galmed Pharmaceuticals GLMD Stock Holding History

Credit Suisse’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-61
Closed -$49K – 4140
2016
Q3 		$49K Buy
+61
New +$46K ﹤0.01% 4021

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Credit Suisse's GLMD Position: Q4 2016 in Review

Credit Suisse sold out of Galmed Pharmaceuticals (GLMD) in Q4 2016, closing a stake of 61 shares — an estimated $49K sold.

Credit Suisse first reported a position in GLMD in Q3 2016 and held it in 1 quarter. The position peaked at $49K in Q3 2016. 13 funds tracked by Wall St. Rank hold GLMD as of Q4 2016.

  • Credit Suisse reported no remaining Galmed Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Credit Suisse sold 61 Galmed Pharmaceuticals shares in Q4 2016, an estimated $49K.
  • Credit Suisse first reported a position in Galmed Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Credit Suisse's Galmed Pharmaceuticals position peaked at $49K in Q3 2016.
  • 13 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.